L. Emens

Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

S. Loi, S. Im, C. Saura, 2019, Poster Discussion Abstracts.

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

A. Chen, H. Tawbi, V. Giranda, 2023, Breast Cancer Research and Treatment.

Immunotherapy Approaches for Breast Cancer Patients in 2023.

S. Loi, L. Emens, 2023, Cold Spring Harbor perspectives in medicine.

296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial

A. Schneeweiss, S. Loi, H. Rugo, 2020 .

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

A. Jazaeri, T. Curiel, A. Mills, 2023, Journal for ImmunoTherapy of Cancer.

A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition

A. Popel, Theinmozhi Arulraj, Cesar A. Santa-Maria, 2023, Science advances.

Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

S. Loi, F. Esteva, C. Saura, 2019, Annals of Oncology.

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.

A. Schneeweiss, S. Loi, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.